SHP-1 agonist SC-43 limits methicillin-resistant Staphylococcus aureus infection through inhibition of heme biosynthesis

The limitations of existing drugs and the development of drug resistance make it urgent to develop new drugs against methicillin-resistant Staphylococcus aureus (MRSA). The re-development of the antibacterial activity of drugs that have already been proven safe for human use is an effective way. In this study, we discovered that the Src homology region 2 domain-containing phosphatase-1 (SHP-1) agonist SC-43, exhibits potent activity against Gram-positive bacteria, including MRSA. The mode of action studies revealed that SC-43 inhibits the key enzyme coproporphyrin ferrochelatase (CpfC) of the coproporphyrin-dependent (CPD) heme synthesis pathway and interferes with the bacterial porphyrin metabolism. The determination of the structure of CpfC derived from S. aureus (SA CpfC ) in this study allowed us to reveal the inhibitory effect of SC-43 at the molecular level. Animal experiments showed that SC-43 has the potential to become a new anti-MRSA drug. In conclusion, this study discovered a new anti-MRSA activity of a drug currently undergoing clinical trials and simultaneously verified the feasibility of developing new anti-Gram-positive bacteria drugs by inhibiting the CPD pathway. The limitations of existing drugs and the emergence of drug resistance make the development of new therapies against methicillin-resistant Staphylococcus aureus (MRSA) increasingly urgent. Here, we demonstrate that the Src homology region 2 domain-containing phosphatase-1 (SHP-1) agonist SC-43 exhibits antibacterial activity against MRSA. The limitations of existing drugs and the emergence of drug resistance make the development of new therapies against methicillin-resistant Staphylococcus aureus (MRSA) increasingly urgent. Here, we demonstrate that the Src homology region 2 domain-containing phosphatase-1 (SHP-1) agonist SC-43 exhibits antibacterial activity against MRSA.